Contingency Management for Stimulant Use Disorders

• Sponsor: University of Virginia (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05097547
• Collaborator: (none)
• Enrollment: 30
• Arm: 1
• Anticipated Duration (Months): 6

Study Details

Study Description

Brief Summary

The invetigators' objective is to implement Medication Assisted Treatment (MAT) and contingency management in patients affected by co-occurring opioid use disorder and stimulant use disorder. Participants will continue to receive standard of care for their opioid use disorder via MAT at our Outpatient Based Opioid Treatment (OBOT) Clinic. Participants' stimulant use disorder will be targeted through contingency management, with twice weekly urine drug screens and monetary prizes in exchange for negative urine drug screens. Through regular clinic visits and the use of incentives, the investigators hope to increase treatment adherence and increase the number of negative urine drug screens in subjects struggling with co-morbid opioid use disorder and stimulant use disorder. The investigators will determine whether or not this treatment is effective in this population, versus conventional treatment (baseline therapy patients were getting through OBOT). The investigators' primary outcome measure will be stimulant abstinence duration during the twelve week study.

Condition or Disease	Intervention/Treatment	Phase
Stimulant Use; Contingency Management	Behavioral: Contingency Management	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Contingency Management for Stimulant Use Disorders
• Anticipated Study Start Date: Oct 1, 2021
• Anticipated Primary Completion Date: Apr 1, 2022
• Anticipated Study Completion Date: Apr 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Contingency management This arm will include data from participants who received CM	Behavioral: Contingency Management; Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.

Outcome Measures

Primary Outcome Measures

1. stimulant abstinence [12 weeks]

   Duration of stimulant abstinence based on urine drug screens

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age 18 and older

• Patients treated for opioid use disorder in the Outpatient Based Opioid Treatment (OBOT) Clinic and who also struggle with stimulant use disorder but failed conventional treatment (positive urine drug screen for substances other than THC and buprenorphine)

• Ideal candidates will test positive for 3 out of 4 weeks or more prior to starting contingency management

Exclusion Criteria:

• Persons under the age of 18

• Persons not able to attend follow-up clinic visits

• Persons not able to consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• University of Virginia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Nassima Ait-Daoud Tiouririne, Principal Investigator, University of Virginia
• ClinicalTrials.gov Identifier: NCT05097547
• Other Study ID Numbers: HSR210335; 17803
• First Posted: Oct 28, 2021
• Last Update Posted: Oct 28, 2021
• Last Verified: Oct 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Oct 28, 2021